{"id":"W4311691578","doi":"10.1016/s2213-2600(22)00437-4","title":"Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study","year":2022,"lang":"en","type":"article","venue":"The Lancet Respiratory Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":221,"is_retracted":false,"has_abstract":false,"ca_institutions":"University Health Network","funders":"","keywords":"Medicine; Crizotinib; Clinical endpoint; Interim analysis; Internal medicine; Progression-free survival; Lung cancer; Oncology; Response Evaluation Criteria in Solid Tumors; Surrogate endpoint; Hazard ratio; Anaplastic lymphoma kinase; Cancer; Surgery; Phases of clinical research; Confidence interval; Randomized controlled trial; Clinical trial; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009601251,0.0002410312,0.001203862,0.0001498673,0.0002595435,0.000009342647,0.000724433,0.00002814459,0.0003891404],"category_scores_gemma":[0.0001344896,0.0001255175,0.0000302581,0.001250116,0.0002325878,0.0001147682,0.0004775715,0.000315397,2.420937e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001376055,"about_ca_system_score_gemma":0.0002254217,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002324667,"about_ca_topic_score_gemma":0.002352112,"domain_scores_codex":[0.9977196,0.0003373467,0.0006879974,0.0004946645,0.0005215793,0.0002388196],"domain_scores_gemma":[0.9968324,0.001042886,0.0005462927,0.001302054,0.000189904,0.00008645768],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.3426362,0.007238528,0.6129161,0.00007912857,0.009834492,0.00004526041,0.01100392,0.001518076,0.0002645155,0.000006688849,0.003503086,0.01095397],"study_design_scores_gemma":[0.5909519,0.006740586,0.3812543,0.00024849,0.01370202,2.777958e-7,0.002458196,0.002330147,0.00007558281,0.000001455355,0.002079061,0.0001579539],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9890739,0.00222271,0.00005049108,0.001237727,0.0001157089,0.004539157,0.002189646,0.00001184286,0.0005588458],"genre_scores_gemma":[0.9970404,0.0001529977,0.000084939,0.0006049286,0.0001183849,0.0002604162,0.001677701,0.00002612098,0.00003414427],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2483157,"threshold_uncertainty_score":0.5118454,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06995470582299267,"score_gpt":0.3998493722953477,"score_spread":0.329894666472355,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}